JPH11510370A5 - - Google Patents

Info

Publication number
JPH11510370A5
JPH11510370A5 JP1997501336A JP50133697A JPH11510370A5 JP H11510370 A5 JPH11510370 A5 JP H11510370A5 JP 1997501336 A JP1997501336 A JP 1997501336A JP 50133697 A JP50133697 A JP 50133697A JP H11510370 A5 JPH11510370 A5 JP H11510370A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997501336A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11510370A (ja
Filing date
Publication date
Priority claimed from US08/476,656 external-priority patent/US6251405B1/en
Application filed filed Critical
Publication of JPH11510370A publication Critical patent/JPH11510370A/ja
Publication of JPH11510370A5 publication Critical patent/JPH11510370A5/ja
Ceased legal-status Critical Current

Links

JP9501336A 1995-06-07 1996-06-05 免疫組合せ組成物および方法 Ceased JPH11510370A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/476,656 US6251405B1 (en) 1995-06-07 1995-06-07 Immunological combination compositions and methods
US08/476,656 1995-06-07
US08/588,621 US6379675B1 (en) 1995-06-07 1996-01-19 Immunological combination compositions and methods
US08/588,621 1996-01-19
PCT/US1996/008866 WO1996040290A1 (en) 1995-06-07 1996-06-05 Immunological combination compositions and methods

Publications (2)

Publication Number Publication Date
JPH11510370A JPH11510370A (ja) 1999-09-14
JPH11510370A5 true JPH11510370A5 (enExample) 2005-05-26

Family

ID=23892726

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9501336A Ceased JPH11510370A (ja) 1995-06-07 1996-06-05 免疫組合せ組成物および方法

Country Status (12)

Country Link
US (5) US6251405B1 (enExample)
EP (1) EP0831937B1 (enExample)
JP (1) JPH11510370A (enExample)
AT (1) ATE249844T1 (enExample)
AU (1) AU717890B2 (enExample)
CA (1) CA2223041A1 (enExample)
DE (1) DE69630033T2 (enExample)
FI (1) FI118591B (enExample)
IL (1) IL118579A (enExample)
NO (1) NO975620L (enExample)
WO (1) WO1996040290A1 (enExample)
ZA (1) ZA964894B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
CN1255850A (zh) * 1997-05-14 2000-06-07 盖伦(化学制品)有限公司 局部用组合物
CA2304128A1 (en) * 1997-09-18 1999-03-25 Robert Becker Improved method of production of pneumococcal surface proteins
EP1087788A1 (fr) * 1998-06-26 2001-04-04 Aventis Pasteur Immunisation a ciblage mucosal
CZ301212B6 (cs) 1998-10-16 2009-12-09 Smithkline Beecham Biologicals S. A. Vakcinacní prostredek
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1980617A1 (en) 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
AT407958B (de) * 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
TR200103018T2 (tr) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
DE60030859T2 (de) 1999-06-18 2007-06-14 The Research Foundation Of State University Of New York Gruppen von borrelia burgdorferi, die lyme krankheit verursachen
CA2390747A1 (en) * 1999-12-09 2001-06-14 Institut Pasteur Systemic immune response induced by mucosal administration of lipid-tailed polypeptides without adjuvant
WO2002009748A1 (en) * 2000-07-31 2002-02-07 Yale University Innate immune system-directed vaccines
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
EP1939294A1 (en) 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi
EP1311540B1 (en) 2000-08-18 2007-12-19 Research Foundation Of State University Of New York Altered ospa of borrelia burgdorferi
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7923023B2 (en) * 2002-02-25 2011-04-12 Astech International LLC Method and composition for delivery of medicants to animals
US20080299140A1 (en) * 2002-05-24 2008-12-04 The Regents Of The University Of California, Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition
FR2846004B1 (fr) * 2002-10-16 2006-06-23 Maco Pharma Sa Composition pour culture de cellules notamment animales ou de tissus, comprenant du polyethylene glycol
US7795223B2 (en) * 2004-05-27 2010-09-14 Novozymes Biopharma Au Ltd. Treatment of inflammatory airway disease
US8029777B2 (en) * 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
EP1789094B1 (en) 2004-08-13 2014-12-10 MARSHALL, Barry J. Bacterial delivery system
EP2476432B1 (en) * 2006-03-07 2015-08-19 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
RU2348406C1 (ru) * 2007-05-02 2009-03-10 Федеральное Государственное Учреждение НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИУТ ДЕТСКИХ ИНФЕКЦИЙ Способ лечения бактериальных гнойных менингитов у детей
TWI376385B (en) * 2007-12-07 2012-11-11 Nat Health Research Institutes Production of lipidated proteins in e. coli
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
US20110105355A1 (en) 2008-04-22 2011-05-05 Research Foundation Of State University Of New York Borrelia burgdorferi cell envelope protein array
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
TWI409275B (zh) * 2009-06-22 2013-09-21 Nat Health Research Institutes 脂質化腫瘤相關抗原及其免疫治療的組成物及方法
US20120237536A1 (en) * 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
WO2012092380A2 (en) 2010-12-29 2012-07-05 Ocean Spar Llc Center spar fish pen
RU2737638C2 (ru) * 2013-12-03 2020-12-01 Вирометикс Аг ПРОЛИН-БОГАТЫЕ ПЕПТИДЫ, ЗАЩИЩАЮЩИЕ ОТ S.pneumoniae
WO2016057562A1 (en) 2014-10-07 2016-04-14 The Research Foundation For The State University Of New York Recombinant borrelia proteins and methods of use thereof
WO2025015077A1 (en) * 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4302386A (en) * 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
EP0014815A3 (de) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
US4258029A (en) 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US4455142A (en) 1980-07-07 1984-06-19 Alza Corporation Method of coadministering an antigen and an immunopotentiator
US4484923A (en) * 1982-03-25 1984-11-27 Alza Corporation Method for administering immunopotentiator
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US4839293A (en) * 1986-02-24 1989-06-13 The Trustees Of Columbia University In The City Of New York DNA encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof
US4721617A (en) 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
EP0270295A3 (en) * 1986-12-03 1989-08-02 Connaught Laboratories Limited Conjugate vaccine
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5098997A (en) * 1987-12-11 1992-03-24 Praxis Biologics, Inc. Vaccines for Haemophilus influenzae
WO1990003441A1 (en) 1988-09-20 1990-04-05 Marvin Murray Accelerated microdilution determination of bacteria susceptibility to antibiotics
ES2092560T5 (es) 1989-12-22 2004-09-16 Mikrogen Molekularbiologische Entwicklungs-Gmbh Proteinas inmunologicamente activas de borrelia burgdorferi, estuches de ensayo relacionados y vacuna.
CA2032914A1 (en) * 1989-12-26 1991-06-27 Peter C.K. Lau Use of bacterial lipoprotein amino terminus in fusion plasmids for in vivo expression of lipid modified polypeptides
JP3215109B2 (ja) 1991-02-15 2001-10-02 ユーエイビー リサーチ ファウンデーション 肺炎球菌タンパクの構造遺伝子
EP0598816B1 (en) * 1991-08-15 1999-06-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Osp a proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
AU681572B2 (en) * 1991-10-21 1997-09-04 Med Immune, Inc. Bacterial expression vectors containing DNA encoding secretion signals of lipoproteins
ES2194010T3 (es) * 1991-10-22 2003-11-16 Symbicom Ab Mejoras en el diagnostico y profilaxis de la borrelia burgdorferi.
CA2105629A1 (en) * 1992-09-14 1994-03-15 Robert S. Becker Potentiation of immunogenic response
WO1994014318A1 (en) * 1992-12-24 1994-07-07 Medimmune, Inc. Method of protection against streptococcus pneumoniae with transformed mycobacteria
FR2708622B1 (fr) * 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.

Similar Documents

Publication Publication Date Title
JP2000500445A5 (enExample)
JP2000500228A5 (enExample)
JP2000500440A5 (enExample)
JP2000500327A5 (enExample)
JP2000500145A5 (enExample)
JP2000500155A5 (enExample)
JP2000500406A5 (enExample)
JP2000500361A5 (enExample)
JP2000502263A5 (enExample)
JP2000500115A5 (enExample)
JPH11512123A5 (enExample)
JP2000500322A5 (enExample)
JP2000500258A5 (enExample)
JP2000500342A5 (enExample)
JP2000500192A5 (enExample)
JP2000500112A5 (enExample)
JP2000509095A5 (enExample)
JPH11510370A5 (enExample)
JP2000500226A5 (enExample)
JP2000500407A5 (enExample)
JP2000500397A5 (enExample)
JP2000500166A5 (enExample)
JP2000500125A5 (enExample)
JP2000500346A5 (enExample)
JP2000500257A5 (enExample)